Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus ...

Get Instant Summarized Text (Gist) Kanglexin (KLX), an anthraquinone compound, shows potential in treating atherosclerosis by inhibiting endothelial-to-mesenchymal transition (EndMT). KLX targets ...

There is an unmet need for novel therapeutics of Dox-induced cardiotoxicity (DIC). We previously identified the protein kinase MAP4K4 as a mediator of DIC. Notably, we showed that blocking MAP4K4 ...

Researchers at the Children’s Hospital of Philadelphia (CHOP) believe a series of rare variants in the MAP4K4 gene is responsible for the condition. The MAP4K4 gene is involved in many signaling ...

MAP4K4 is a serine/threonine kinase that belongs to the MAP kinase family and plays a critical role in embryogenesis and cellular migration. It contains approximately 1,200 amino acids and has a ...

The discovery identified the disorder in 21 families from all over the world. The study "Abrogation of MAP4K4 protein function causes congenital anomalies in humans and zebrafish" is published in ...

Insilico Medicine IP Ltd. has described new TRAF2 and NCK-interacting protein kinase (TNIK) and/or mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4; HGK; MEKKK4) inhibitors reported to ...

miR-30d expression is selectively enriched in cardiomyocytes, induced by hypoxic stress and is acutely protective, targeting MAP4K4 (mitogen-associate protein kinase 4) to ameliorate apoptosis.

ST recruitment of STRIPAK facilitates PP2A-mediated dephosphorylation of MAP4K4 and induces cell transformation through the activation of the Hippo pathway effector YAP1. These observations identify ...